Hirotsu Bio Science, a medical venture developing a cancer screening tool using nematodes, has secured ¥30 million in funding from Shinkin Capital Co. to accelerate growth in overseas markets, the firm announced Thursday.
The Tokyo-based venture run by Takaaki Hirotsu, formerly a biology researcher at Kyushu University, is creating a method to detect early-stage cancers with nematodes, which he discovered are attracted to the diluted urine of cancer patients.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.